Alliance Global Partners analyst James Molloy initiated coverage of Vaccitech with a Buy rating and $12 price target. The firm’s target is “primarily” based on its projections for lead candidates VTP-300 in development to treat chronic hepatitis B, or HBV, infection and VTP-200 to treat chronic human papillomavirus, or HPV, infection, the analyst tells investors. Alliance’s sum-of-the-parts analysis values VTP-300 for chronic HBV at $7 per share, VTP-200 for HPV at $3 per share and values the remaining potential indications for VTP-600, VTP-850, VTP-1000, VTP-1100 plus cash at $2 per share.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VACC:
- Vaccitech downgraded to Equal Weight from Overweight at Morgan Stanley
- Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023
- Vaccitech announces upcoming milestones
- Vaccitech reports Q2 EPS (62c), consensus (55c)
- Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
